CHICAGO--(BUSINESS WIRE)--Massive Bio, a global leader in AI-enabled oncology trial access and precision oncology navigation, today announced that it will unveil the next phase of Reticulum NexusTM, its trusted multi-agent oncology intelligence ecosystem, during the 2026 American Society of Clinical Oncology Annual Meeting in Chicago. Reticulum Nexus is designed to address one of oncology’s most persistent failures: the gap between the rapid pace of cancer innovation and the ability of patients,